Catalyst Pharmaceuticals (NASDAQ:CPRX) reported fourth-quarter and full-year 2025 results that management said reflected ...
2don MSN
Catalyst forecasts 21–26% FIRDAPSE revenue growth in 2026 while expanding AGAMREE market penetration
Q4 2025 Management View Richard John Daly, President and CEO, stated that "2025 was defined by notable growth as evidenced by another year of record revenues, execution of our strategy to maximize the ...
Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total RevenuesQ4 ...
Catalyst's management team will host a conference call and webcast on Thursday, February 26, at 8:30 AM ET to discuss the Company's financial results and provide a business update.
Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% YoY, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0 Million, an ...
CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel ...
The webcast will be available under the Investors section on the Company's website, www.catalystpharma.com, and a replay will be available for at least 30 days. About Catalyst Pharmaceuticals, Inc.
Zacks Investment Research on MSN
Here's why Catalyst Pharmaceutical (CPRX) is a strong momentum stock
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...
CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Daniel Curran, MD, to its Board of ...
CORAL GABLES, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, ...
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results